Replies to post #123990 on Biotech Values

[acgood]

Quote:
Is there any concern about the effect of TPO agonists on cancer progression and/or survival, as there is with the ESAs?
Excellent question.

Since I had to look this up, thought I would share the link:
http://www.medscape.com/viewarticle/717033

So it looks like the ESA issue only was identified from a meta analysis after the fact? I am not clear on the details/design of the promacta cancer trials to know if such an issue would likely be identified

[ghmm]

Here is one study looking at bone marrow from AML patients.
http://www.ncbi.nlm.nih.gov/pubmed/19710504

That thought has actually crossed my mind and I was wondering if GSK was deliberately being selective in the cancer indications they try but I don't have the science background to even make an educated guess :-).